TLC I-16

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameTLC I-16
Drug Alias NameN/A
ClassificationDiagnostic agent (In vivo)
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Liposome Company Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Liposome Company Inc
Active IndicationsN/A
Inactive IndicationsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A